Avoid piperacillin-tazobactam when treating BSI cause by ceftriaxone-resistant pathogens

(European Society of Clinical Microbiology and Infectious Diseases) The antibiotic combination treatment piperacillin-tazobactam was significantly less effective than meropenem when treating potentially fatal bloodstream infections (BSI) caused by ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae and should be avoided when treating these organisms, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).